VTVT
vTv Therapeutics Inc.Price
Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).
Signal stack
Where each data set points today.
- InsidersNO TRADES
No open-market buys or sells in 12 months. Recent filings are awards, exercises and tax withholding.
- InstitutionsMIXED
Q3 2026: 5 added (0 new), 5 trimmed or exited.
- AnalystsBULLISH
12 of 13 rate it Buy or better. Every target is above the price.
- EstimatesFALLING
Current-quarter EPS estimate −$1.153 → −$1.220 over 90 days. 2 up, 0 down in 30 days.
- Short sellersSTEADY
Short interest +1.4% to 145.4K shares. 8.2 days to cover, ≈3.6% of shares.
- TrendDOWNTREND
36% below its 50-day average. New closing low $17.69 on Nov 16.
Who's buying
13F· Q3 2026| Fund | Move | Value |
|---|---|---|
| GEODE CAPITAL MANAGEMENT, LLC | TRIM | $751.7K |
| HRT FINANCIAL LP | DOUBLED | $745.0K |
| MARSHALL WACE, LLP | TRIM | $736.6K |
| MORGAN STANLEY | DOUBLED | $539.0K |
| VANGUARD FIDUCIARY TRUST CO | TRIM | $374.1K |
| UBS Group AG | DOUBLED | $349.1K |
| Vanguard Global Advisers, LLC | TRIM | $10.4K |
| BNP PARIBAS FINANCIAL MARKETS | NEAR_EXIT | $278.00 |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
13 analystsPrice is below the lowest target. Median implies +222%.Targets as of Nov 17, 2026.
| Date | Firm | Rating |
|---|---|---|
| Oct 14, 2026 | BTIG REITERATE | Buy |
| Aug 6, 2026 | HC Wainwright & Co. MAINTAIN | Buy |
| Jul 16, 2026 | BTIG MAINTAIN | Buy |
Insider ledger
Form 4| Insider | Type | Value |
|---|---|---|
AKKARAJU SRINIVAS Director Jun 26, 2026 | AWARD | $210.5K |
Al-Marzooqi Fahed Director Jun 26, 2026 | AWARD | $210.5K |
Phillips Anne M. Director Jun 26, 2026 | AWARD | $210.5K |
SPIEGELMAN DANIEL K Director Jun 26, 2026 | AWARD | $210.5K |
BAKER BROS. ADVISORS LP Director Jun 26, 2026 | AWARD | 6,000 sh |
Earnings setup
Estimates| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | -$1.22 | -$1.46–-$1.04 | -4.3% | $0.00 |
| Next Q | -$1.08 | -$1.21–-$1.00 | +2.3% | $0.00 |
| Current FY | -$2.04 | -$4.07–-$1.09 | +7.9% | $30.7M |
| Next FY | -$3.87 | -$4.81–-$2.46 | +17.7% | $0.00 |
Short side
FINRA· Oct 30, 2026SecBot reports
7 filings · 2 press releases · 0 bullish · 0 bearish · 7 neutral- NEUTRAL SC 13D/ANov 16, 2026
Samsara BioCapital filed Amendment No. 4 to its Schedule 13D, reporting a slight reduction in its aggregate beneficial ownership to 9.9% (capped by a blocker) due to a small block sale of 61,287 shares by Samsara LP on November 12, 2026. The filing does not disclose any new demands or changes in…
🔒 Fresh report (last 24h), subscribers only
- NEUTRAL 144Nov 12, 2026
Samsara BioCapital, L.P., a major shareholder, filed Form 144 to sell 61,287 shares of vTv…
The filing is an advance notice of intent to sell by a significant institutional holder. Monitor whether the sale actually executes and if additional insider selling follows; the small size relative…
- NEUTRAL 8-KNov 5, 2026
vTv Therapeutics reported Q3 2026 net loss of $11.6M ($0.94 per share), wider than the $8.7M loss…
The key catalyst is the Phase 3 CATT1 topline data readout in mid 2027. Cash runway appears sufficient through that event. The FDA Orphan Drug Designation for HPPD may support partnering discussions…
- NEUTRAL PRESS-RELEASENov 5, 2026
vTv Therapeutics reported a Q3 2026 net loss of $11.6M ($0.94 per share), wider than the $8.7M…
The next major catalyst is the Phase 3 CATT1 topline data readout in mid 2027. Monitor cash runway updates and any partnering discussions for HPPD, which could provide non-dilutive funding.
All VTVT filing & press-release reports (9)
- SC 13D/A reportNov 16, 2026
- 144 reportNov 12, 2026
- 8-K reportNov 5, 2026
- PRESS-RELEASE reportNov 5, 2026
- SC 13G/A reportOct 8, 2026
- DEFA14A reportJun 10, 2026
- PRESS-RELEASE reportMay 8, 2026
- PRESS-RELEASE reportMar 10, 2026
- 8-K reportFeb 26, 2026